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Abstract
Melatonin kills or inhibits the proliferation of different cancer cell types, and this is associ-
ated with an increase or a decrease in reactive oxygen species, respectively. Intracellular
oxidants originate mainly from oxidative metabolism, and cancer cells frequently show alter-
ations in this metabolic pathway, such as the Warburg effect (aerobic glycolysis). Thus, we
hypothesized that melatonin could also regulate differentially oxidative metabolism in cells
where it is cytotoxic (Ewing sarcoma cells) and in cells where it inhibits proliferation (chon-
drosarcoma cells). Ewing sarcoma cells but not chondrosarcoma cells showed a metabolic
profile consistent with aerobic glycolysis, i.e. increased glucose uptake, LDH activity, lactate
production and HIF-1α activation. Melatonin reversed Ewing sarcoma metabolic profile and
this effect was associated with its cytotoxicity. The differential regulation of metabolism by
melatonin could explain why the hormone is harmless for a wide spectrum of normal and
only a few tumoral cells, while it kills specific tumor cell types.
Introduction
Ewing sarcoma is the second most frequent primary bone tumor after osteosarcoma, account-
ing for 10–15% of these pathologies. It primarily affects children and young adults, with a peak
incidence in the second decade of life. Nowadays, a combination of chemotherapy, surgery and
radiation therapy results in 65% of patients free of disease after 4 years in those without metas-
tases at diagnosis. However, even using the best combination of chemotherapy, surgery and
radiation, 24–35% of patients still relapse, and this percentage is strikingly higher if patients
had metastasis at diagnosis [1].
Antitumoral effects of melatonin have been extensively described in a wide variety of tumor
cell types. This indolamine inhibits proliferation in the majority of tumor cells through several
possible intracellular signaling pathways [2] including antioxidant actions [3–5]. However, mela-
tonin is also able to kill some specific tumor types, such as Ewing sarcoma or hematological
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malignancies, by means of both the extrinsic and the intrinsic pathways of apoptosis [6,7]. More-
over, we have previously shown that melatonin not only kills Ewing sarcoma cells, but also shows
synergy with vincristine, ifosfamide and other chemotherapeutic drugs currently used to treat
this disorder [8,9].
Melatonin has been well characterized as a potent antioxidant, and its neuroprotective and
antiproliferative effects are tightly associated with a decrease in reactive oxygen species (ROS)
[4]. However, melatonin effects on tumor cells do not always correspond with an antioxidant
effect. In fact, previous data obtained in our laboratory indicate that the cytotoxicity of melato-
nin in Ewing sarcoma cells is mediated by an increase in ROS [10]. Such increase in ROS has
been also described in other tumor cells where melatonin cytotoxicity was also reported
[11,12]. Many anticancer agents work by further increasing cellular levels of ROS, to overcome
the antioxidant detoxification capacity of the cancer cell and induce cell death [13]. However,
based on previous data, it seems clear that the fate of tumor cells following administration of
melatonin is dependent on the intracellular redox state (antioxidant for antiproliferative effects
vs. prooxidant for cytotoxic effects). But why the same molecule decreases intracellular oxi-
dants in most normal and tumoral cells but increases free radicals in other specific types of
tumors? Given that melatonin is an antioxidant in vitro [14], it is likely that its pro-oxidant
effect in some tumors is indirect and due to intrinsic characteristics of specific tumor cells.
Energy metabolism accounts for the production of most intracellular ROS, and it is fre-
quently altered in cancer [15,16]. The metabolic needs of highly proliferating tumor cells differ
from normal cells, but also between different types of cancer [17]. Most tumor cells have an
increased glucose uptake, allowing them to obtain higher amounts of pyruvate that is then used
as an energy source, as it is converted to lactate in a process called aerobic glycolysis or War-
burg effect [18]. This method of production of ATP is much less efficient than oxidative phos-
phorylation, but acceleration of glycolysis after increasing glucose uptake compensates for its
inefficiency. Importantly, the contribution of the Warburg effect to energy metabolism is very
marked in some tumors, but reduced or inexistent in others [19].
We hypothesized that melatonin could have different effects (antiproliferative vs cytotoxic)
on tumoral cells depending on their intrinsic glycolytic metabolism. We show for the first time
that melatonin regulates this metabolism, inhibiting the hallmarks of Warburg effect in Ewing
sarcoma cells. Such inhibition is associated to the inactivation of HIF-1α, the main regulator of
aerobic glycolysis, and to melatonin´s cytotoxicity.
Material and Methods
Cell culture and reagents
sw-1353 (chondrosarcoma) and A-673(Ewing sarcoma) cell lines were purchased from Ameri-
can Type Culture Collection (Teddington, United Kingdom) and TC-71 and A-4573 (Ewing
sarcoma) cell line were a generous gift from Dr J.A. Toretsky (Departments of Oncology and
Pediatrics, Georgetown University, Washington DC, USA). Cells were maintained at 37°C in a
humidified atmosphere of 5% CO2, and subcultured once a week using a 0.25% trypsin solu-
tion. Cell culture reagents were purchased from Sigma (Sigma Chemical Co., St Louis, MO,
USA) except for fetal bovine serum (FBS), which was purchased from Gibco (Invitrogen Life
Technologies, Barcelona, Spain). Culture flasks and dishes were obtained from Falcon (Becton
Dickinson BioScience, Le Pont de Claix, France). Melatonin and all other reagents were pur-
chased from Sigma (Sigma- Aldrich, St Louis, MO, USA), unless otherwise indicated.
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Evaluation of cell number and cell death
For MTT assays, cells were seeded onto 96-well plates and the method described by Denizot
[20] was followed. Basically, once the treatments were completed, 10 μl of a MTT solution in
PBS (5 mg/mL) were added. After 4 hr of incubation at 37°C, one volume of the lysis solution
[sodium dodecyl sulphate (SDS) 20% and dimetylformamide pH 4.7, 50%] was added. The
mixture was incubated at 37°C overnight and the samples were measured in an automatic
microplate reader (μQuant, Bio-Tek Instruments, Inc., Winooski, VT, USA) at the wavelength
of 540 nm.
The released lactate dehydrogenase (LDH) was used as an additional index of cytotoxicity.
For this assay, cells were seeded onto 24-well plates. Determination of total and released LDH
activity was accomplished following specifications of the lactic dehydrogenase based In Vitro
Toxicology Assay Kit (Sigma-Aldrich, St Louis, MO, USA). Absorbance was determined using
an automatic microplate reader (μQuant; Bio-Tek Instruments, Inc., Winooski, VT, USA) at
490 nm.
Trypan blue uptake is indicative of irreversible membrane damage preceding cell death, giv-
ing as a result a blue staining in non-viable cells. After treatments cells were harvested and
resuspended in 800 μl of PBS and 200 μl of 0.4% trypan blue solution. Three replicates were
counted in a Neubauer hemacytometer chamber (Sigma- Aldrich, St Louis, MO, USA). The
number of non-stained and stained cells was counted and the percentage of viable and non-via-
ble cells was calculated.
Flow cytometry
Rhodamine 123 was used to monitor the electrochemical gradient in mitochondria (ΔCm).
Cells were plated in 6-well dishes and, 24 hours later, incubated with Rhodamine 123 (1 μg/ml)
in serum-free medium for 20 min at 37°C in the dark. Cells were collected, resuspended in
PBS, and incubated with propidium iodide (2 μg/ml) for 10 min at room temperature in the
dark. Rhodamine 123 fluorescence of 10,000 live cells per group was measured in a Beckman
Coulter FC500 flow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA).
Measurement of glucose uptake activity using 2-NBDG
Glucose uptake activity was measured using a fluorescent D-glucose analogue 2-[N-(7-nitro-
benz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG). Cells were seeded in
96-well plates. After treatment, cells were washed with PBS and incubated with 10 μM
2-NBDG for 35 min. Fluorescence was measured in a microplate fluorimeter FLX-800 (Bio-
Tek Instruments, Inc., Winooski, VT, USA) at an excitation wavelength of 467 nm and an
emission wavelength of 542 nm.
Measurement of intracellular lactate levels
Cells were seeded in 150 mm plates and lactate concentration was determined using the Lactate
Assay Kit (Sigma- Aldrich, St Louis, MO, USA) according to the manufacturer's protocol.
Absorbance was measured at 570 nm using an automatic microplate reader (μQuant; Bio-Tek
Instruments, Inc., Winooski, VT, USA).
Colorimetric measurement of glycogen concentration
Glycogen intracellular levels were determined by using the Glycogen Assay Kit (Sigma- Aldrich,
St Louis, MO, USA) following a modification of the manufacturer´s protocol. Cells were seeded
in 150 mm plates, treated as described, collected and homogenized (2x106) in 100 μl of ice-cold
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water. Reactions were carried out following manufacture´s protocol and absorbance was mea-
sured at 570 nm using an automatic microplate reader (μQuant, Bio-Tek Instruments, Inc.,
Winooski, VT, USA).
Electron microscopy analysis
After melatonin treatment, cells were fixed with 3% glutaraldehyde (Fluka, Buchs, Switzerland)
in 0.1 M phosphate buffer pH 7.3 for 30 min. Cells were then postfixed in 2% w/v OsO4 con-
taining 1.25% w/v potassium ferrocyanide, dehydrated in a graded series of acetone solutions
and embedded in Spurr resin (Low viscosity embedding kit, EMS, Fort Washington, PA, USA).
Finally, blocks were polymerized at 70°C for 48 hr. Ultrathin sections (70–90 nm) were
obtained using an Ultracut E ultratome (Reichert-Jung, Wien, Austria), stained with 2% p/v
uranyl acetate and lead citrate, and photographed with a JEOL 1011 transmission electron
microscope (100KV) (Zeiss, Overkochen, Germany) equipped with a system that incorporates
a digital photograph camera of 11 Mpixels (Gatan Inc., München, Germany). At least 200 cells
on each experimental group were analyzed.
Determination of ATP levels
Quantitative determination of ATP was carried out by means of the ATP Determination Kit
(Molecular Probes, Invitrogen, USA), following manufacturer´s protocol. The assay is based
on luciferase's requirement for ATP to produce luminescence. Cells were plated in 6-well plates
and lysed in 300 μl of lysis buffer (100 mM potassium phosphate pH 7.2, 2 mM EDTA, 1 mM
DTT, 1% v/v Triton) and kept overnight at -20°C. Ten μl of sample were loaded on 96-well
white plates, and luminescence was quantified in a microplate luminometer (Thermo Scientific
Varioskan Flash, Thermo Fisher Scientific Inc., Waltham, MA, USA). Luminescence was then
normalized with sample protein concentration as determined by Bradford assays (Protein
Assay, BIO-RAD Laboratories, Hercules, CA).
Western Blot Analysis
For protein expression analysis, cells were seeded on 100 mm plates. After treatments, cells
were lysed with ice-cold lysis buffer (150 mMNaCl, 1mM EDTA, 1 mM EGTA, 1% v/v Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mMNa3VO4, 1 μg/mL
leupeptin, 2 μg/ml aprotinin, 1 μg/ml pepstatin-A, 110 nM NaF, 1 mM PMSF, 20 mM Tris–
HCl pH 7.5). Thirty micrograms of total protein were separated by SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes (Amersham Biosci-
ence, Pittsburgh, PA, USA). Blots were incubated overnight at 4°C with appropriate antibodies:
hydroxylated-HIF- 1α (1:1000, Cell Signaling, Danvers, MA, USA), phosphorylated AKT
(anti-phospho-AKT 1:1000, Cell Signaling, Danvers, MA, USA) and phosphorylated mTOR
(anti-phospho-mTOR 1:1000, Cell Signaling, Danvers, MA, USA) as well as glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as a loading control (1:5000, Santa Cruz Biotechnology,
Dallas, TX, USA). Immunoreactive polypeptides were visualized using horseradish peroxidase
conjugated secondary antibodies (anti-rabbit IgG peroxidase conjugated 1:4000; Santa Cruz
Biotechnology, Dallas, TX, USA) and enhanced-chemiluminescence detection reagents (Amer-
sham Bioscience, GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) following manufacturer-
supplied protocols. Inmunoblots were analyzed by means of Un-Scan-It Gel 6.0 (Gel graph
Digitizing Software-Silk Scientific Corporation, Utah, USA) to provide quantitative values for
relative expression of each protein (normalized to its own loading control).
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Data analysis
Results are represented as the average value of at least three independent experiments. Data
are represented as the mean +/- SEM. Significance was tested by one-way ANOVA followed
by a Student-Newman-Keuls multiple range test. Statistical significance was accepted when
P 0.05.
Results
Ewing sarcoma cells but not chondrosarcoma cells exhibit features of
Warburg effect
Most cancer cells frequently display a metabolic profile different to normal cells. They have
higher rates of cytosolic glycolysis, uptaking more glucose and producing an excess of lactic
acid [18,21]. We evaluated these parameters characteristic of the tumoral Warburg effect in
two sarcoma cell lines: sw-1353 chondrosarcoma cells (which stop proliferating in the presence
of melatonin) and TC-71 Ewing sarcoma cells (which are killed by melatonin). As shown in
Fig 1A, TC-71 Ewing sarcoma cells consumed higher levels of glucose than sw-1353 chondro-
sarcoma cells. This is accompanied by an increased lactate production and lactate dehydroge-
nase (LDH) activity (Fig 1B and 1C), suggesting an increase in fermentative metabolism in TC-
71 cells in comparison to sw-1353 cells. TC-71 cells also exhibited lower levels of ATP (Fig 1D)
and a less significant mitochondrial membrane potential (ΔCm) than sw-1353 cells (Fig 1E).
Inhibition of LDH by oxamate in the TC-71 cell line caused cell death, indicating that this met-
abolic pathway is essential for their survival (Fig 1F). All results together show an evident dif-
ference in basal energy metabolism between chondrosarcoma and Ewing sarcoma cells, which
in turn may be related to the differential effect of melatonin on both cell types. In those cells
where we found Warburg effect (TC-71) melatonin induces cell death [8,10], whereas in those
cells that present “normal” glycolytic metabolism with little or no participation of the aerobic
glycolysis (sw-1353) melatonin inhibits cell proliferation [10].
Opposite effects of melatonin in glucose metabolism in Ewing sarcoma
and chondrosarcoma cells
In order to identify the possible effect of melatonin in aerobic glycolysis we studied first glucose
uptake in the presence or absence of the hormone. Melatonin induced a rapid decrease in glu-
cose uptake in TC-71 Ewing sarcoma cells significant after 8 hours of treatment (Fig 2A). This
decrease in glucose uptake after 8 hours of treatment was observed also in two other Ewing sar-
coma cell lines, A-4573 and A-673 (Fig 2B). Decreased glucose availability could force TC-71
cells to use intracellular glucose stores (glycogen) in order to obtain energy. Melatonin actually
abolished glycogen reservoirs that were easily observed by electron microscopy in control
groups both as dense granules free in the cytoplasmic matrix and forming rosettes (Fig 2C).
Biochemical determination of glycogen levels confirmed a drastic decrease in glycogen levels
after 4 hours not only in TC-71 cells but also in A-4573 and A-673 cells (Fig 2D). Moreover,
CP316819, a specific inhibitor of glycogen breakdown, strongly enhanced melatonin-induced
Fig 1. Ewing sarcoma cells exhibit the main hallmarks of Warburg effect. The following parameters indicative of aerobic glycolysis were determined in
TC-71 and sw-1353 cell lines (*p0.05 vs. sw-1353 cell line, unless otherwise indicated): (A) Glucose uptake (relative fluorescence units, RFU); (B)
Intracellular lactate levels (nmoles/μl); (C) LDH activity, normalized versus protein content; (D) ATP levels (millimoles of ATP/μg protein); and (E)
Mitochondrial membrane potential (ΔΨm) was expressed as RFUs. (F) TC-71 cells were treated with or without 16.2 mM oxamate for 48 hours, and cell
survival rate was determined by means of trypan blue staining. Results were expressed as a percentage of death cells. *p0.05 vs. vehicle-treated cells.
doi:10.1371/journal.pone.0135420.g001
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cell death in TC-71 cells (Fig 2E), indicating that normal glycogen breakdown was essential for
cell viability.
In contrast, melatonin induced an increase in glucose uptake in sw-1353 chondrosarcoma
cells (Fig 3A) and, consistently, it did not induce glycogen breakdown (Fig 3B and 3C). In addi-
tion, CP316819 did not alter melatonin antiproliferative effects (Fig 3D).
Melatonin inhibits fermentative metabolism in Ewing sarcoma cells but
not in chondrosarcoma cells
A hallmark of the Warburg effect is that pyruvate is reduced to lactate instead of entering the
Krebs cycle and undergoing oxidative phosphorylation (OXPHOS) [22]. Our data shows that
intracellular lactate levels (Fig 4A) and LDH activity (Fig 4B) were significantly reduced in TC-
71 cells after treatment with melatonin for 24 hours. The inhibitory effect in LDH activity and
lactate production is not exclusive from TC-71 cells but extended to A-4573 and A-673 Ewing
sarcoma cell lines (Fig 4C). Moreover, the LDH inhibitor oxamate significantly enhanced mela-
tonin toxicity in the three Ewing sarcoma cell lines (Fig 4D). These data indicate that fermenta-
tive metabolism is essential for Ewing sarcoma cells survival and its blockage by melatonin,
oxamate or both is lethal.
In contrast to Ewing sarcoma, melatonin did not induce changes in intracellular lactate lev-
els or LDH activity in sw-1353 chondrosarcoma cells (Fig 4E and 4F). Consistently, oxamate
was not toxic neither potentiated melatonin antiproliferative effect (data not shown). It seems
that chondrosarcoma cells are preferentially using another energy pathway different from fer-
mentative metabolism, which is not regulated by melatonin.
Activation of the master regulator of oxygen homeostasis HIF-1α is essential for mainte-
nance of Warburg effect [23]. As shown in Fig 5, melatonin induced a significant increase in
the inactivated (hydroxylated) form of HIF-1α in TC-71 (Fig 5A), A-4573 and A-673 cells
(Fig 5B), which is consistent with its inhibition of Warburg effect. PI3K/AKT/mTOR signaling
can increase HIF-1α activity by inducing its stabilization, and we and others have shown that
melatonin regulates the PI3K/AKT/mTOR pathway in some tumor types [5,24]. However,
melatonin activated AKT and mTOR in TC-71 (Fig 5C), A-4573 and A-673 cells (Fig 5D),
which is not consistent with the inactivation of HIF-1α. On the other hand, rapamycin or
LY294002, specific inhibitors of mTOR and PI3K respectively, did not prevent melatonin-
induced decrease in TC-71 cell viability (Fig 5E, left panel). Both inhibitors reduced the phos-
phorylation of their target proteins, as expected, and none of them modified HIF-1α expression
(Fig 5E, right panel). These data suggest that PI3K/AKT/mTOR activation may not be respon-
sible for HIF-1α regulation by melatonin in Ewing sarcoma cells, and therefore this pathway is
probably not involved in melatonin toxicity.
Fig 2. Melatonin inhibits glucose uptake and depletes glycogen stores in Ewing sarcoma cells. (A) Glucose uptake was measured in TC-71 cells
treated with o without 1 mMmelatonin for several times (2h, 4h, 6h and 8h). Data are expressed as RFU (relative fluorescence units). (B) Glucose uptake
was measured in A4573 and A-673 cells treated with o without 1 mMmelatonin for 8h. Data are expressed as RFU (relative fluorescence units). (C) Electron
microscopy images showing the decrease in glycogen stores after treatment of Ewing sarcoma cells with 1 mMmelatonin for 24 hours. Black arrows indicate
glycogen stores that appear at cytoplasm forming rosettes. Also dense granules of glycogen can be observed free in the cytoplasm in control groups. N,
nucleus; m, mitochondria; G, golgi apparatus areas. Right images on each experimental group correspond to a higher magnification of left image. Bars: 1μm
(left image) /0.5μm (right image). (D) Intracellular glycogen levels were assessed in TC-71, A-4573 and A-673 cells after incubation with 1 mMmelatonin for 4
hours. (E) Cell death was determined by means of the LDH-release assay. Ewing sarcoma cells were treated with or without 1 mMmelatonin and 10 μM
CP316819 for 72 hours, and cell death was calculated as the ratio between released and total LDH activity on each experimental group. Data are expressed
as the percentage of control (vehicle-treated cells).*p0.05 vs. vehicle-treated cells; #p0.05 vs. melatonin-treated cells.
doi:10.1371/journal.pone.0135420.g002
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Discussion
Melatonin proapoptotic effect in some cancer cell types has been extensively studied in recent
years, but the exact mechanism remains unknown. We show for the first time that melatonin
cytotoxic effect is related to an inhibition of Warburg effect in Ewing sarcoma cells.
Fig 3. Melatonin does not inhibit aerobic glycolysis in chondrosarcoma cells. (A) Glucose uptake was determined in sw-1353 chondrosarcoma cells
treated with o without 1 mMmelatonin for several times (2h, 4h, 6h and 8h). Data are expressed as RFU (relative fluorescence units). (B) Melatonin effects on
glycogen stores were evaluated in sw-1353 cells incubated with 1 mMmelatonin for 24 hours, by means of electron microscopy. Black arrows indicate
glycogen stores that appear at cytoplasm forming rosettes. Also dense granules of glycogen can be observed free in the cytoplasm in both control and
melatonin treated groups. N, nucleus; m, mitochondria; G, golgi apparatus areas. Bars: 0.5μm. (C) Intracellular glycogen levels were assessed in sw-1353
cells after incubation with 1 mMmelatonin for 4 and 24 hours. (D) Chondrosarcoma cells were treated with or without 1 mMmelatonin and 10 μMCP316819
for 72 hours, and cell number was determined by the quantification of total LDH present in cell culture. Data are expressed as the percentage of control
(vehicle-treated cells). *p0.05 vs. vehicle-treated cells.
doi:10.1371/journal.pone.0135420.g003
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Reprogramming of energy metabolism is a capability involved in the pathogenesis of most
tumors, and has become one of the main hallmarks of cancer. This theory relies on previous
research conducted by Otto Warburg [18], who hypothesized that most tumor cells obtain
energy mainly by transformation of glucose to lactate rather than oxidizing pyruvate into the
mitochondria. This process, known as Warburg effect or aerobic glycolysis, is triggered by
alterations in signaling pathways involved in glucose uptake and metabolism, which in turn
can also regulate mitochondrial metabolism [25]. The mitochondrial electron transport chain
and OXPHOS are the main sources of cellular ROS and, therefore, alterations in mitochondrial
metabolism could have consequences for the intracellular REDOX state of tumoral cells.
Melatonin is a well-known antioxidant and has various effects at mitochondrial level and,
most importantly, we and others have shown that its antitumoral effects are related with its
regulation of the intracellular REDOX state. Thus, inhibition of cell proliferation correlates
with a decrease in intracellular ROS, while melatonin cytotoxic effects are associated with an
increase in oxidative stress [10]. The results presented here indicate that the different effects of
melatonin could be related to differences in the metabolic pattern of cancer cells.
Ewing sarcoma cells show an increased basal glucose uptake, higher levels of intracellular
lactate and LDH activity, lower ATP production and decreased mitochondrial functionality in
comparison to chondrosarcoma cells. Inhibition of LDH activity kills cancer cells that are met-
abolically dependent on the Warburg effect [26] and, consistently, oxamate kills Ewing sar-
coma cells but not chondrosarcoma cells. These results strongly suggest that the metabolism of
TC-71 cells, but not chondrosarcoma cells, relies on aerobic glycolysis and the Warburg effect.
Our results also suggest that melatonin inhibits glycolytic metabolism of Ewing sarcoma
cells but not of chondrosarcoma cells. It induces a decrease in glucose uptake, lactate levels and
LDH activity, and enhances oxamate cytotoxic effect, further confirming that aerobic glycolysis
is essential for the survival of Ewing sarcoma cells. Besides external supply, cells can also obtain
glucose from the degradation of glycogen, the major intracellular glucose storage. Thus, mela-
tonin´s inhibition of glucose uptake could cause the breakdown of glycogen stores observed in
Ewing sarcoma cells, possibly due to an attempt to obtain energy and maintain cell viability.
This is confirmed by the fact that blockage of glycogen breakdown enhances the toxicity of
melatonin and is highly lethal for these cells. Inhibition of glycogen phosphorylase- enzyme
that breaks down glycogen into glucose subunits- triggers apoptotic cell death due to the
absence of energetic substrate in some tumor types [27], like melatonin does. Blockage of gly-
colytic metabolism currently constitutes a major target to prevent cancer growth, with various
experimental treatments being already tested in preclinical studies. These include genetic or
pharmacological inhibition of glycolytic enzymes or LDH [28–30]; or the use of non-metabo-
lizable analogues, such as 2-Deoxyglucose (2-DG) [31; 32] or 3-Bromopyruvate [33]. Many of
these treatments prevent tumor progression, induce an increase in ROS production and kill
cancer cells [30], again consistent with melatonin effects in Ewing sarcoma cells.
Melatonin inactivates HIF-1α in Ewing sarcoma cells, which could account for the decrease
in aerobic glycolysis. This transcription factor is primarily responsible for the increase in glyco-
lytic activity in most cancer cells, allowing them to survive. Its activation is essential for cancer
Fig 4. Aerobic glycolisis is inhibited bymelatonin in Ewing sarcoma cells. (A) Lactate levels (nmoles/μl) were quantified in TC-71 cells treated with 1
mMmelatonin for 2, 4, 6 and 24 hours. (B) LDH activity was evaluated in TC-71 cells incubated with 1 mMmelatonin for several times (2h, 4h, 6h and 24
hours), and results were normalized with protein content (μg) in each sample. (C) Intracellular lactate levels and LDH activity were evaluated in A-4573 and
A-673 Ewing sarcoma cells treated with 1 mMmelatonin for 24 hours. Data are represented as percentage versus control group. (D) Cell viability (% of death
cells) was evaluated by trypan blue after the incubation of TC-71, A4573 and A-673 Ewing sarcoma cells with 1mMmelatonin and 16.2 mM oxamate for 48
hours. (E) Intracellular lactate levels (nmoles/μl) were quantified in sw-1353 chondrosarcoma cells treated with 1 mMmelatonin for 2, 4, 6 and 24 hours. (F)
LDH activity was evaluated in sw-1353 chondrosarcoma cells incubated with 1 mMmelatonin for 2, 4, 6 and 24 hours, and results were normalized with
protein content (μg) in each sample. *p0.05 vs. vehicle-treated cells; #p0.05 vs. melatonin-treated cells.
doi:10.1371/journal.pone.0135420.g004
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Fig 5. Melatonin inhibits HIF-1α in a PI3K/AKT/mTOR independent pathway.Western blot analyses were carried out to identify the effect of melatonin (1
mM, 4 and 8 hours) on the activation of HIF-1α in TC-71 cells (A) and A-4573 and A-673 (1mM, 4 hours) cells (B). AKT and mTOR activation in TC-71 (C) and
Melatonin Regulation of Warburg Effect in Cancer Cells
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cells to exhibit Warburg effect, since it increases the activity of the vast majority of the enzymes
involved in aerobic glycolysis even under normoxic conditions [23]. Inhibition of the transcrip-
tion factor HIF-1α has been repeatedly suggested as a therapeutic target against cancer, because
of its key role in the Warburg effect could allow fine control of tumor growth [34]. In this sense
melatonin has been described to decrease invasion and cell migration by blocking HIF-1α in
some tumor types [35]. Furthermore, in hypoxic environments, melatonin is able to decrease
HIF-1α expression levels in several tumor types [36]. Finally, in vivo antitumoral and anti-
angiogenic effects of melatonin have been also suggested to be mediated by a decrease in HIF-
1α expression [37]. Although there are a number of studies relating the activation of PI3K/
AKT/mTOR pathway with the activation of HIF-1α [38,39], and melatonin regulates the
PI3K/AKT/mTOR pathway in several models [5,24], our results show that these events are not
connected in Ewing sarcoma cells.
Taken together, the data presented in this work demonstrate the ability of melatonin to reg-
ulate aerobic glycolysis or Warburg effect in cells highly dependent on this metabolic pathway,
such as Ewing sarcoma cells. This effect is closely associated with its toxicity in these cells.
Given that fermentative metabolism is currently considered a possible therapeutic target in the
fight against cancer, we should consider melatonin, alone or in combination with other antitu-
moral agents, as a possible tool deserving further attention. Identifying the intracellular mecha-
nisms by which melatonin is able to control this metabolism is of special interest to understand
why some tumor types are sensitive to its antitumoral effects while others are not. Such under-
standing could lay the groundwork for the development of new personalized therapeutic strate-
gies, based on a match between specific drugs and the intrinsic features of each cancer. Thus,
the relevance of our findings stems from the fact that melatonin could be used most efficiently
as a personalized antitumoral agent, if we were able to determine the metabolic profile of each
tumor in patients in vivo or in biopsies of their tumors.
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